TILT Biotherapeutics

“Scius provided invaluable communications support in announcing clinical data for our lead product TILT-123 at important international medical conferences. We secured excellent international media coverage and exposure in Nordic outlets, spotlighting our innovative approach in cancer immunotherapy. Scius’ strategic support has been helpful in positioning TILT at the forefront of the oncolytic viral therapy space.”

Aino Kalervo
COO of TILT Biotherapeutics

Objectives

Showcase Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at prestigious medical congresses AACR and ASCO.
Generate international trade media and local coverage.
Position TILT as a leader in oncolytic viral therapies and highlight its pioneering approach in cancer treatment.

Strategy

Drafted comprehensive press releases highlighting clinical data and promising early results.
Showcasing TILT-123 and its potential for IV delivery and systemic impact on tumours.
Conducted targeted outreach to international trade media and facilitated interviews with key oncology focused publications writing on ASCO.

Results

Showcased data as part of key conference highlights from AACR/ASCO 2024.
Featured in major trade media outlets such as Drug Discovery World and secured in depth feature in ONCOLife.
Secured coverage in Nordic Life Science News and other local press.